 price
report earn even top/bottom line
beat strong earli trikafta launch near term
growth come continu trikafta strength ex-u
reimburs contract expans address cf
popul said outer-year estim high rapid
trikafta adopt may compress growth along price-to-earnings
multipl heighten import pipelin
drive share higher investor focu
program particular
full note updat outlook/perform slide pt
increas
impress trikafta launch revenu
oct approv ahead consensu estim
inventori stock expect remain rel
switcher het-min popul previous elig
guidanc provid revenu
ahead consensu estim assum
growth run rate ex trikafta inventori
build readili achiev given
trajectori franchis
aatd updat come
compani sound confid approv pathway
patient identif though remain key area
rest pipelin evolv though earli addit crsp
data expect semma program
move clinic late
inhibitor pain discontinu due pk/toler
increas trikafta growth
concurr decreas orkambi symdeko kalydeco
reduc outer year opex
revenu net effect pt increas
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect
object report investor consid report singl factor make invest decis
cf franchis pois strong growth beyond
make progress ex-u reimburs
well posit earli trikafta approv number ex-
us reimburs contract come on-board uk
franc spain fuel strong growth beat/rais may drive
stock perform outer year estim could move
higher addit reimburs updat trikafta
smooth orkambi/symdeko given efficaci
cf opportun fulli price ex-u reimburs
histor slow- like similar trikafta
outer year cf number alreadi high reach limit
upsid franchis
addit mani challeng ex-u
reimburs orkambi/symkevi like seen trikafta
well given larger address popul ex-u price like continu
come scrutini trikafta label expans number may
need come
aatd could multi-billion opportun similar approach
estim patient aatd us/eu
anoth larg opportun aatd approach similar
cf correct misfold protein compani demonstr
abil fda workshop note flexibl endpoint approv
path registr may rel quick
build promis pipelin
beyond cf aatd number interest shot goal
includ pain partnership crsp beta thal/sickl cell
diseas recent acquir semma/exon add earlier stage
program still time left build pipelin intern
bd cf franchis continu grow
clinic develop pathway aatd flux like
fda workshop highlight focu clinic endpoint approv
like need part vrtx pivot program diagnosi aatd low
pose addit challeng market competitor advanc
well rnai next-gen ert gene edit may prove
superior alon combin
pipelin riski earli valuat assum clinic
success beyond cf durabl patent
much vrtx pipelin beyond cf meaning clinic commerci
risk dev focus earli platform technolog beyond
compani core compet small molecul develop size cf
franchis difficult replac patent expir small
molecul franchis face quick eros exact time cf
franchis expiri isnt entir clear could sooner expect
updat path forward
advanc clinic
advanc clinic
late earli
combin sg
revenu report trial old
ongoing- submit snda popul
approv australia children
reimburs england spain australia
approv kalydeco children age
month
chmp posit opinion eu infant
complet evalu singl
multipl dose hv announc plan
plan initi
data studi
hv on-going
on-going aatd
first pt dose studi scd
enrol on-going scd beta
thal data expect
addit data
reimburs sweden age
expand price agreement germani
children approv eu children
approv us infant age
month approv canada children age
month
pt treat clinic studi tdt
track design grant tdt
scd first pt enrol scd us
enrol tdt scd
final data expect plan
submit nda eu either
program
on-going enrol cf children age
nda submit fda
on-going enrol cf children age
mutat
one minim function mutat
submit ema cf age trikafta
approv us
posit recommend symdeko
australia pbac
approv symdeko us
submiss eu plan
reimburs england spain australia
advanc follow-on program pain
combo w/
grant fda
studi hv expect complet
initi pend result
initi studi
expand collabor crispr
form kymera
hv on-going pain track
design grant fda
discontinu pain advanc follow-on
complet semma therapeut
sg
 sg
non-
strong demand
symdeko posit
feedback patient
physician well strong
coverag symdeko
across public
first saw signific
increas number
patient treat
approv medicin
result
 multipl label
expans kalydeco
orkambi
complet key
around world secondli
excel progress
phase
revenu neg
impact channel
inventori build
occur end
higher gross net
adjust typic
experienc earli
uptak symdeko
 recent launch
symkevi germani
expans younger
us age two five
year orkambi
age year
trikafta launch ex-u
compar consensu estim gener bullish outer year estim
vrtx cf franchis us ex-u
drug price increasingli come focu us show vrtx ww total
product payer split medicar part medicaid commerci us ex-u us
revenu account chang govern price could trickl commerci
plan howev due high unmet need cf competit discount remain
minim portfolio wide expect
overal minim expect impact base current circul propos
vrtx fourth cf program trikafta tripl regimen cf recent approv us
patient year old least mutat approv statu compani
program also shown notabl eu approv trikafta also expect
cf patient homozyg mutat ii
one copi certain mutat result residu
cf patient homozyg mutat
ii one copi mutat one copi
certain mutat result residu cftr activ
cf patient homozyg mutat ii
one copi certain mutat result residu
cf patient homozyg mutat
ii one copi mutat one copi
certain mutat result residu cftr activ
cf patient homozyg mutat
cf patient homozyg mutat
cf patient homozyg mutat
cf patient homozyg mutat
cf patient one specifi
mutat cftr gene
cf patient one specifi
mutat cftr gene
cf patient one specifi
mutat cftr gene
cf patient one specifi
mutat cftr gene
month specif
specif mutat
cf patient least one mutat cftr
cf patient least one mutat cftr
trikafta elexacaftor-tezacaftor-ivacaftor approv earli us follow strong data
importantli approv increas address popul het-min patient addit
chart show benefit seen popul improv vs pbo
tezacaftor/ivacaftor homozygot substanti higher benefit orkambi/symdeko
approv increas address mutat though lower address popul given
age restrict current approv patient year old estim account
total age group
trikafta recent approv us add het-min popul vrtx address
follow launch late octob
approv oct report first
quarter sale even
sale substanti beat
consensu estim though
inventori record
expect roughli stabl go
note see uptak
segment popul patient
switch cftr modul
het-min patient werent previous
elig well new patient initi
compani expect continu
patient growth though consid
persistence/compli
high program
trikafta launch impress start though still earli know plateau
indic patient ww current elig kalydeco orkambi
symdeko base approv mutations/ag group
addit compani note trikafta approv patient us
previous address exist therapi expans het-min popul
trikafta approv europ territori address popul
expect increas total cf popul least mutat
total patient
also advanc gene edit mrna approach potenti treat remain
continu expand address cf popul trikafta expect reach
show current estim address popul size vrtx therapi
base approv age mutat cover also includ potenti address popul
ex-u trikafta approv assum year age group similar us also
expect file year old estim add address patient trikafta
popul us
least
heterozyg
homozyg
yr yet
yet
least
heterozyg
total address popul assum eventu age expans vrtx therapi
patient us patient ex-u
use number show total potenti market opportun cf
use differ price penetr assumpt
refer outer-year consensu estim reach
consensu estim cf franchis high achiev given unmet need
popul less clear meaning upsid left
import recent reimburs updat ex-u territori
drive strong revenu growth patient come on-board see next slide detail
del homozyg het-min addit exist agreement
symdeko del homozyg del mutat
symdeko del homozyg del mutat
kalydeco w/
symdeko del homozyg del mutat
kalydeco w/
current futur cf drug
orkambi pathway
access futur drug
symdeko kayldeco del homozyg del
symdeko del homozyg del respons rf
orkambi futur drug
kalydeco approv gate mutat
kalydeco approv gate
substanti discuss nh final
announc access agreement oct
orkambi/symdeko expand access kalydeco
symkevi/ivakaftor homozyg pt
kalydeco gate mutat
estim elig england total
french author approv nation reimburs
orkambi
note orkambi avail homozygot
year old sinc dec temporari use though
increas access yr old pt current
orkambi franc
recognit record low valu sale
franc book one-tim catch-up non-gaap revenu
differ contract book revenu
expand agreement includ
trikafta year old
approv europ kalydeco
orkambi symdeko alreadi
avail dec
previous indic
patient cf ireland
spanish government approv term
orkambi symkevi kalydeco
reimburs oct
homozygot approv heterozygot
note elig cf pt
agreement australia symdeko
expand access orkambi
orkambi expand access includ
symdeko yr old homozygot
note cf pt
recent ex-u reimburs updat describ facilit strong sale
growth new pt come on-board exist therapi addit trikafta launch
continu innov cf beyond approv therapi next-gen small molecul
program technolog
compani advanc daili version kalydeco deuter ivakaftor well
daili tripl tezakaftor
addit also partnership crsp gene edit mrna
approach may abl address addit popul elig
bid kalydeco
corrector/potenti
mutat
mutat
studi complet clinicaltri gov
beyond approv program also advanc addit approach cf includ
next-gen oral small molecul well mrna/gen edit approach unclear extent
deuter strategi confer durabl franchis exclus
competit landscap cf therapi shown overal immin threat
vrtx cf franchis low follow modest result compani includ pti
glpg gene therapy/mrna/gen edit approach advanc lung pose
challeng deliveri particularli cf therapi need cross mucu layer
stage develop
bind receptor
addit small molecul program mrna gene edit approach advanc note
previou slide recent present updat sad portion studi
greatest increas seen mid-dos patient mg dose group
individu maxim increas mean maximum increas
baselin
 patient treat experienc improv day mg averag
mg
inconsist term dose response/dur vs might expect
note small dataset over-interpret data inconsist disadvis
recent present result sad portion studi earli data
present result mad portion
result across vrtx program shown trikafta overal profil pois transform
care pt improv efficaci vs orkambi symdeko broader
ab chang
increas rhinorrhea rhiniti influenza sinus blood bilirubin
pt headach nausea sinu congest dizzi
alt ast
alt ast
sae relat elev
worsen liver function
rash nausea dizzi
alt ast
trikafta safeti profil roughli line kalydeco symdeko safeti profil superior
orkambi reflect switch symdeko launch
type patent
composit matter
composit matter
composit matter
composit matter
composit matter
composit matter
composit matter
composit matter
composit matter
composit matter
method use
method use
method use
method use
method use
method use
method use
method use
method use
method use
method use
method use
lumakaftor ivakaftor combin
tezakaftor ivakaftor combin
tezakaftor ivakaftor combin
tezakaftor ivakaftor combin
tezakaftor ivakaftor combin
orang book patent vrtx cf program shown current com patent
reach till late program addit formul patent might weaker
said note pend com patent trikafta reach
beyond cf key focu vrtx effort antitrypsin diseas aatd
compani develop two small molecul corrector
diseas caus mutat gene result abnorm protein
fold product common mutat result fold defect main
liver build-up abnorm lead liver damag caus fibrosis/cirrhosi
lung aat function lung inhibit neutrophil elastas cleav elastin structur
protein lung without function elev neutrophil elastas level caus lung
structur degrad damag lead emphysema copd
key focu beyond cf effort aatd result expect
present preclin data piz transgen mous model highlight
abil increas function human level plasma reduct liver
aggreg shown
addit detail program rel limit compani note assay
measur function secret abil inhibit neutrophil elastas
complet sad/mad studi healthi volunt initi studi
patient pizz genotyp copi allel primari endpoint chang plasma level
vs pbo day result expect
compani also advanc earlier stage program includ second corrector
preclin result encourag though somewhat limit detail first read
biomark data expect
augment therapi approv treat aatd though evid support benefit
mix date
studi test aatd non-smok patient random receiv zemaira placebo
benefit lung densiti chang vs pbo though improv seen time first exacerb
fda aatd workshop agenc note given lack correl lung densiti
clinic endpoint longer consid relev clinic endpoint confirm efficaci
meta-analys found lack consist benefit treat patient though potenti
benefit moder popul slow slope declin vs untreat patient
reason limit benefit shown augment therapi isnt fulli understood might relat
sub-optimal pk profil slow rate declin overal popul
although abl increas serum level evid clinic benefit augment
therapi controversi
spite mix clinic benefit seen augment therapi current
annual billion revenu
said despit high preval number patient global aatd remain substanti
underdiagnos given symptom resembl lung diseas includ copd liver diseas
result potenti market opportun therapi address lung manifest like
mani fold higher exist augment therapi substanti effort need
augment therapi current annual billion potenti effect therapi much
higher though patient identif key hurdl
primari endpoint vrtx studi serum level day focu
determin level might confer normal phenotyp
studi shown homozyg zz patient high risk emphysema liver diseas wherea
heterozyg mz patient one normal copi one allel least level
low risk lung/liv diseas normal level rang nearli
said still need demonstr protein produc adequ function
capabl assay measur abil inhibit neutrophil elastas function activ
addit recent fda workshop indic there clinical/epidemiolog evid
suggest increas level protect zz patient may higher neutrophil/n burden
evid strong serum level would encourag start though question
degre function secret protein also need answer
oct fda workshop review develop pathway aatd program key focu
endpoint
per commentari workshop fda suggest pre-approv may accept demonstr
posit pre-defin trend clinic endpoint
said also note work compani determin relev endpoint base
fda may accept demonstr posit pre-defin trend
one clinic endpoint seriou
exacerb exercis capac symptom provid advers
trend seen clinic endpoint
fda may accept demonstr posit pre-defin trend
one clinic endpoint seriou
exacerb exercis capac symptom side
provid advers trend seen endpoint
possibl demonstr function benefit may requir approv
hasnt yet given sens design pivot studi
program
stage asset
cand
compani develop oral corrector aatd could address liver
lung manifest diseas rnai therapi could correct liver diseas next-gen
augment therapies/or elastas inhibitor could address lung theoret gene edit
approach may abl correct well still pre-proof-of-concept
anoth late-stag pipelin effort develop non-opioid pain medic target
lead program complet proof concept studi knee osteoarthr
small fiber neuropathi bunionectomi
express peripher nociceptor inhibitor could provid efficaci without cross
earli similar attempt focus though may abl better thread needl
said slow advanc pivot trial also develop follow-on
program discontinu lack optim safety/toler pk advanc
addit molecul clinic develop
opioid epidem precipit need
block action potenti transmit pain
signal peripher nervou system could logic
advanc portfolio inhibitor pain lead program complet
earli attempt pathway modul target due genet evid congenit
insensit pain patient mutat genet locu encod
howev earli attempt make inhibitor fail inhibitor also block close relat
ion channel target inhibit could lead arrhythmia could lead partial
compar lower sequenc homolog channel may abl avoid
toxic concern
drug select target like
pns-specif
low sequenc homolog
inhibitor may abl avoid off-target toxic seen program
vrtx inhibitor poc separ pain indic
effect
womac scale
pb week
treatment effect
drop dpn
behavior ideat
unspecifi ae vs
pb
patient
patient pb
discontinu
sae arm
sae
dizzi
efficaci roughli line
detail exact caus discontinu
data across indic investig shown reason efficaci addit
preclin program move clinic
also advanc program focal segment
glomerulosclerosi fsg mediat
fsg character scar glomerulu
kidney
apolipoprotein bound
circul hdl express multipl organ
includ kidney
found copi risk
allel confer meaning higher risk high
develop fsg
said mechan variant caus
vrtx lead program fsg
small molecul inhibitor sad/mad
studi complet compani move
endpoint expect proteinuria
estim peopl us
advanc toward initi mediat fsg
collabor crsp tdt/scd gene program
collabor crsp advanc program ex vivo gene-edit
autolog stem cell transplant edit induc fetal hemoglobin product
potenti cur treatment tdt sickl cell diseas
tdt data present shown
patient tdt mutat hereditari persist fetal hemoglobin hb
known nearli asymptomat abl achiev hb pt
tbd hold pt tougher pt well
outcomes/dur compar lentiglobin differ moa hbf induct
earli promis data expect
collabor crsp advanc program ex vivo gene-edit
autolog stem cell transplant edit induc fetal hemoglobin product
potenti cur treatment tdt sickl cell diseas
scd data present shown
blue lentiglobin shown reduct hb correspond signific decreas voc infus
also lead hb increas trend hb howev note hbf higher antisickl
properti hba even higher hb may suffic crsp tbd data avail
mechan action
autolog hsct
knock
enrol preliminari data pt report
proof concept present asgct
mechan action
autolog hsct
hgb studi start hgb data regulatori updat
hsc transduc lvv encod
knock
interim data announc alreadi eha addit analysi due
singl center academ trial enrol data on-going basi
trial run sni initi
aruv also beta thal
studi on-going last data present potenti updat year
beta thal
increas clinic evid sever product could potenti cur room still open new product
besid zynteglo bar high given multi-year durabl observ to-dat zynteglo
hemoglobin last
biomarkerind graft
relat vector integr
observ
associ drug
product grade hgb-
northstar
teae typic
associ autolog stem-
sae two
episod veno-occlus liver
diseas attribut busulfan
sae northstar
observ scd patient treat
year infus
-thal pt
sae sever allerg reaction
infus rapidli
resolv medic
prbc
transfus week
autolog transplant none
relat drug product
sae subsequ resolv
pneumonia
presenc
neutropenia veno-
attribut busulfan
pt free
time last
transfus last
follow
time
treatment last
g/dl
patient
g/dl
dose
patient
follow
g/dl
dose
patient
follow
pt dose
pediatr
dose lower
requir
ind
g/dl
week
expand
hbf total hb
infus week
neutrophil platelet recoveri
within week infus
indelshav detect
per erythroid precursor cell
addit data bone marrow
vcn
infus
infus
program
technolog use repair genet mutat
precis single-cut system minimum
dystrophin gene exon delet
rod domain restor orf thu
technolog leverag amen
dystrophin restor level rang
normal level depend
skelet muscl cranial tibiali
heart tongu
histolog normal appear
fewer necrot fiber reduc edema
fibrosi inflammatori cell infiltr
show sequenc alter
safeti observ
posit cell infiltr treat muscl
littl genet correct
suffici restor dystrophin normal
dystrophin express restor
skelet myofib effici express
cardiomyocyt
employe
signific expertis
experi novo nordisk
novarti regeneron prior work
focus metabol skelet muscl
experi develop manufactur
process gt program platform
proven experi advanc
biotherapeut preclin stage
full clinic develop
extens experi gene therapi
manipul gene express
unmet need type diabet
million adult children preval
islet cell transplant known
preval patient elig islet
pt extrem sensit
high risk recurr seriou hypoglycemia
limit islet transplant technolog
limit donor cadaver-deriv islet
poor engraft function /durabl differenti
host respons immun reject fibrosi
consequ need immunosuppress
semma
use stem-cel deriv pancreat islet cell treat
uniqu aspect semma technolog
abil produc larg quantiti
function human pancreat beta cell restor
insulin secret amelior hypoglycemia
novel devic encapsul protect
cell immun system enabl
durabl implant without need on-going
type cell
differenti
donor-specif
respons
-cell
mix -cell
cell also
capabl
ipsc
microspher
human
inject pouch
allow
improv
drop
reduct daili
player
earli
point
market
larg
enough
list price increas sinc launch drug
 sale
 sale
 sale
npv
target market cap impli pt
target ev impli pt
upsid price
collabor royalti revenu net
net incom
ep share
number basic share
number dilut share
usdmm except otherwis state
flow oper activ
depreci amort expens
chang work capit
prepaid expens asset
accru expens liabil
oper
flow invest activ
purchases/sal invest
matur market secur
purchas market secur
paymet acquir busi
net cash use provid invest activ
flow financ activ
issuanc common stock benefit plan
repurchas common stock
payment financ leas
advanc collabor
net cash provid financ activ
effect chang exchang rate cash
net increas cash cash equival
cash equival restrict cashbegin period
cash equival restrict cashend period
prepaid expens current asset
cash equivalentsend period
deriv pt dcf use termin growth rate discount rate
ex-u reimburs cystic fibrosi product price pressur market product pipelin risk
articl articl
time dissemin januari
analyst josh schimmer vivek sivathanu angela ni maneka mirchandaney primarili respons prepar research
report attest follow view opinion render research report reflect person view subject
compani issuer part research analyst compens directli relat specif
recommend view research report
